|
Sign In to gain access to subscriptions and/or personal tools.
|
Prognostic factors for survival in multiple sclerosis
Z M Levi
Institute of Neurology, School of Medicine, University of Belgrade, Dr Suboti a 6, Belgrade 11 000, Yugoslavia
I Dujmovi
Institute of Neurology, School of Medicine, University of Belgrade, Dr Suboti a 6, Belgrade 11 000, Yugoslavia
T Pekmezovi
Institute of Epidemiology, School of Medicine, University of Belgrade, Vi egradska 26a, Belgrade 11 000, Yugoslavia
M Jarebinski
Institute of Epidemiology, School of Medicine, University of Belgrade, Vi egradska 26a, Belgrade 11 000, Yugoslavia
J Marinkovi
Institute of Biostatistics, Public Health and Research in Medicine, School of Medicine, University of Belgrade, Dr Suboti a 15, Belgrade 11 000, Yugoslavia
N Stojsavljevi
Institute of Neurology, School of Medicine, University of Belgrade, Dr Suboti a 6, Belgrade 11 000, Yugoslavia
J Drulovi
Institute of Neurology, School of Medicine, University of Belgrade, Dr Suboti a 6, Belgrade 11 000, Yugoslavia
In a hospital-based study of 119 patients with definite multiple sclerosis, demographic and clinical factors were analysed with respect to their validity in assessing the long-term prognosis. Over a mean follow-up of 21.7 years, the following factors negatively influenced the prognosis by the univariate analysis: male sex, age at onset over 25, pyramidal involvement or spasticity at onset, 53 functional systems affected at onset or after 5 years, incomplete first remission, length of the first remission 41 year, 45 attacks in the first 10 years, secondary or primary-progressive disease, time to reach secondary progression over 5 years and time to reach EDSS 6 over 7 years. The multivariate model showed that in patients with relapsing-remitting disease, 5 years after onset, pyramidal involvement at onset and shorter time to reach EDSS 6 predicted poor outcome, while after 10 years, higher age at onset and incomplete first remission indicated poor prognosis. Ten years after onset, the predictors of poor outcome in the secondary-progressive group were shorter time to reach EDSS 6 or secondary progression and higher EDSS, while in the primary-progressive group those variables were spasticity or higher number of functional systems affected at onset, and higher EDSS after 5 and 10 years.
Key Words: multiple sclerosis course prognosis survival analysis multivariate analysis clinical features demographic features
Multiple Sclerosis, Vol. 5, No. 3,
171-178 (1999)
DOI: 10.1177/135245859900500306

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. Smestad, L. Sandvik, and E. Celius
Excess mortality and cause of death in a cohort of Norwegian multiple sclerosis patients
Multiple Sclerosis,
November 1, 2009;
15(11):
1263 - 1270.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
C Hirst, G Ingram, R Swingler, D A S Compston, T Pickersgill, and N P Robertson
Change in disability in patients with multiple sclerosis: a 20-year prospective population-based analysis
J. Neurol. Neurosurg. Psychiatry,
October 1, 2008;
79(10):
1137 - 1143.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J Drulovic, T Riise, M Nortvedt, T Pekmezovic, and M Manigoda
Self-rated physical health predicts change in disability in multiple sclerosis
Multiple Sclerosis,
August 1, 2008;
14(7):
999 - 1002.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Tremlett, Yinshan Zhao, and V. Devonshire
Natural history of secondary-progressive multiple sclerosis
Multiple Sclerosis,
April 1, 2008;
14(3):
314 - 324.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Leray, S. Morrissey, J. Yaouanq, M. Coustans, E. Le Page, J. Chaperon, and G. Edan
Long-term survival of patients with multiple sclerosis in West France
Multiple Sclerosis,
August 1, 2007;
13(7):
865 - 874.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Tremlett, D. Paty, and V. Devonshire
Disability progression in multiple sclerosis is slower than previously reported
Neurology,
January 24, 2006;
66(2):
172 - 177.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. D Simmons, A.-L. Ponsonby, I. A. van der Mei, and P. Sheridan
What affects your MS? Responses to an anonymous, Internet-based epidemiological survey
Multiple Sclerosis,
April 1, 2004;
10(2):
202 - 211.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
R. K. Burt, B. A. Cohen, E. Russell, K. Spero, A. Joshi, Y. Oyama, W. J. Karpus, K. Luo, B. Jovanovic, A. Traynor, et al.
Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores
Blood,
October 1, 2003;
102(7):
2373 - 2378.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. L. Simone, D. Carrara, C. Tortorella, M. Liguori, V. Lepore, F. Pellegrini, A. Bellacosa, A. Ceccarelli, I. Pavone, and P. Livrea
Course and prognosis in early-onset MS: Comparison with adult-onset forms
Neurology,
December 24, 2002;
59(12):
1922 - 1928.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. A. van Walderveen, G. J. Lycklama a Nijeholt, H. J. Ader, P. J. H. Jongen, C. H. Polman, J. A. Castelijns, and F. Barkhof
Hypointense Lesions on T1-Weighted Spin-Echo Magnetic Resonance Imaging: Relation to Clinical Characteristics in Subgroups of Patients With Multiple Sclerosis
Arch Neurol,
January 1, 2001;
58(1):
76 - 81.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|